BackStrategic Partners A/S Overview
Strategic Partners A/S

Strategic Partners A/S Return on Equity

Valuation check: OZYMF's ROE is -10.23%, below the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

-10.23%

Return on Equity

-10.23%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Strategic Partners A/S (OZYMF) FAQ

Strategic Partners A/S posts a ROE of -10.23%. That is below the Healthcare sector average of 13.1%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 13.1% is typical. Strategic Partners A/S's -10.23% is lower that level. That is roughly 178.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Strategic Partners A/S's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -10.23%; use YoY and peer views to separate noise from signal.

Context for OZYMF's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.1%), and (3) consistency with growth and profitability. This page covers the first two; Strategic Partners A/S's other metric pages and overview cover the third.

Judging Strategic Partners A/S against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -10.23% here, then scan peer and history charts to see if the gap is persistent.